orchestrating metabolic homeostasis: the role of gut hormones in next-generation therapies for metabolic syndrome

Metabolic disorders, including obesity and type 2 diabetes, have reached epidemic proportions globally, necessitating novel therapeutic approaches. the gut-brain axis, particularly gut hormones, plays a crucial role in metabolic regulation, offering promising targets for intervention.this review aims to synthesize current knowledge on gut hormone-based therapies for metabolic disorders, focusing on their mechanisms of action and therapeutic potential.gut hormones, including glp-1, gip, pyy, ghrelin, and oxyntomodulin, orchestrate complex physiological responses to nutrient intake, influencing insulin secretion, appetite, and energy expenditure. recent advancements in incretin-based therapies, particularly glp-1 receptor agonists and dual glp-1/gip agonists, have shown remarkable efficacy in improving glycemic control and promoting weight loss. these therapies exploit the synergistic actions of multiple gut hormones, offering a more comprehensive approach to metabolic regulation. emerging research on pyy analogs and ghrelin antagonists further expands the therapeutic landscape. however, challenges remain in optimizing delivery methods, ensuring long-term efficacy, and mitigating potential side effects.gut hormone-based therapies represent a paradigm shift in the management of metabolic disorders. by harnessing the intricate signaling networks of the gut-brain axis, these innovative approaches offer the potential for more effective and targeted interventions in obesity and type 2 diabetes, paving the way for personalized treatment strategies in metabolic medicine.